Analyst Marie Thibault from BTIG maintained a Buy rating on Embecta Corporation and keeping the price target at $22.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Marie Thibault has given his Buy rating due to a combination of factors that highlight both stability and emerging growth drivers for Embecta. She views the company’s core diabetes business as resilient, with management consistently meeting financial objectives even while managing headwinds in China, U.S. pricing pressure, and channel-related volume shifts, and she expects international strength and a second-half recovery in China supported by a new value-focused pen needle.
Thibault also emphasizes Embecta’s evolving strategy to become a broader medical supplies platform, including GLP-1–related pen needle opportunities with more than 30 pharma partners and incremental upside from the pending Owen Mumford acquisition, which should expand manufacturing capabilities and third-party product distribution. In her view, the 2026 guidance framework, disciplined execution, and additional optionality from partnerships justify maintaining the $22 price target, which implies attractive value at roughly 7x her forward adjusted EPS estimate.